Adenoviral Vectors in Gene Therapy

Authors: M. Pjechová 1;  L. Hernychová 1;  P. Tomašec 1,2;  G. W. Wilkinson 1,2;  B. Vojtěšek 1
Authors‘ workplace: Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno 1;  Department of Medical Microbio­logy, Institute of Infection and Immunity, School of Medicine, Cardiff University, United Kingdom 2
Published in: Klin Onkol 2015; 28(Supplementum 2): 75-80
doi: 10.14735/amko20152S75


This review is focused on gene therapy, especially adenovirus vectors and their relationship with the immune system response. Adenovirus vectors belong to the most used gene delivery vehicles in gene therapy, study of gene expression or immunotherapy. One of the most important questions concerning their use is their influence on organism in vivo. Study of immunomodulating properties of the adenovirus vectors opens a way for further manipulation and their more effective practical use.

Key words:
gene therapy –  adenoviridae –  immune system

This study was supported by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101), by the project MEYS – NPS I – LO1413 and by (MH CZ – DRO (MMCI, 00209805).

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

2. 4. 2015

20. 7. 2015


1. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science 1972; 175(4025): 949– 955.

2. Sheridan C. Gene therapy finds its niche. Nat Biotechnol 2011; 29(2): 121– 128. doi: 10.1038/ nbt.1769.

3. Kwiatkowska A, Nandhu MS, Behera P et al. Strategies in gene therapy for glioblastoma. Cancers 2013; 5(4): 1271– 1305. doi: 10.3390/ cancers5041271.

4. Zhao F, Tian J, An L et al. Prognostic utility of gene ther­apy with herpes simplex virus thymidine kinase for patients with high‑grade malignant gliomas: a systematic review and meta analysis. J Neurooncol 2014; 118(2): 239– 246. doi: 10.1007/ s11060‑ 014‑ 1444‑ z.

5. Herman JM, Wild AT, Wang H et al. Randomized phase III multi‑institutional study of TNFerade bio­logic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol 2013; 31(7): 886– 894. doi: 10.1200/ JCO.2012.44.7516.

6. Li Y, Li LJ, Wang LJ et al. Selective intra‑ arterial infusion of rAd‑ p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. BMC Med 2014; 12: 16. doi: 10.1186/ 1741‑ 7015‑ 12‑ 16.

7. Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte‑ macrophage colony‑ stimulating factor‑encoding, second‑ generation oncolytic herpesvirus in pa­cients with unresectable metastatic melanoma. J Clin Oncol 2009; 27(34): 5763– 5771. doi: 10.1200/ JCO.2009.24.3675.

8. Fillat C, Jose A, Bofill‑ De Ros X et al. Pancreatic cancer gene therapy: from molecular targets to delivery systems. Cancers 2011; 3(1): 368– 395. doi: 10.3390/ cancers3010368.

9. Leja J, Nilsson B, Yu D et al. Double‑detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One 2010; 5(1): e8916. doi: 10.1371/ journal.pone.0008916.

10. Ginn SL, Alexander IE, Edelstein ML et al. Gene therapy clinical trials worldwide to 2012 –  an update. J Gene Med 2013; 15(2): 65– 77. doi: 10.1002/ jgm.2698.

11. Russell SJ, Peng KW, Bell J. Oncolytic virotherapy. Nat Biotechnol 2014; 30(7): 658– 670. doi: 10.1038/ nbt.2287.

12. McCart JA, Ward JM, Lee J et al. Systemic cancer ther­apy with a tumor‑ selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61(24): 8751– 8757.

13. Khuri FR, Nemunaitis J, Ganly I et al. A controlled trial of intratumoral ONYX‑ 015, a selectively‑ replicating adenovirus, in combination with cisplatin and 5- fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6(8): 879– 885.

14. Mansfield D, Pencavel T, Kyula JN et al. Oncolytic Vac­cinia virus and radiotherapy in head and neck cancer. Oral Oncol 2013; 49(2): 108– 118. doi: 10.1016/ j.oraloncology.2012.07.019.

15. Kanai R, Rabkin SD, Yip S et al. Oncolytic virus‑ mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012; 104(1): 42– 55. doi: 10.1093/ jnci/ djr509.

16. Doerfler W, Boehm P (eds). The molecular repertoire of adenoviruses. Berlin: Springer 1995.

17. Stewart PL. Adenovirus structure. In: Curiel DT, Douglas JT (eds). Adenoviral vectors for gene therapy. San Diego: Academic Press 2002: 1– 18.

18. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6 (Suppl 1): S164– S171.

19. Alba R, Bosch A, Chillon M. Gutless adenovirus: last‑ generation adenovirus for gene therapy. Gene Ther 2005; 12 (Suppl 1): S18– S27.

20. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988; 163(2): 614– 617.

21. He T, Zhou S, da Costa LT et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95(5): 2509– 2514.

22. Stanton RJ, McSharry BP, Armstrong M et al. Re‑ engeneering adenovirus vector systems to enable high‑through­put analzses of gene fiction. Biotechniques 2008; 45(6): 659– 668.

23. Jiang H, Wang Z, Serra D et al. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti‑ad antibodies. Mol Ther 2004; 10(6): 1140– 1142.

24. Appledorn DM, McBridge A, Seregin S et al. Complex interaction withseveral arms of the complement system dictate innate and humoral imunity to adenoviral vectors. Gene Ther 2008; 15(24): 1606– 1617. doi: 10.1038/ gt.2008.114.

25. Cerullo V, Seiler MP, Mane V et al. Toll‑like receptor 9 trig­gers an innate immune response to helper‑dependent adenoviral vectros. Mol Ther 2007; 15(2): 378– 385.

26. Chen RF, Lee CY. Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection. INt Rev Immunol 2014; 33(1): 45– 53. doi: 10.3109/ 08830 185.2013.823420.

27. Tomasec P, Wang EC, Groh V et al. Adenovirus vector delivary stimuletes natural killer cell recognition. J Gen Virol 2007; 88(4): 1103– 1108.

28. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81(11): 2573– 2604.

29. Farina SF, Gao GP, Xiang ZQ et al. Replication‑ defective vector based on a chimpanzee adenovirus. J Virol 2001; 75(23): 11603– 11613.

30. Kremer EJ, Boutin S, Chillon M et al. Canine adenovirus vectors: an alternative for adenovirus‑ mediated gene transfer. J Virol 2000; 74(1): 505– 512.

31. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector imunity: its implications and circumvention strategies. Curr Gene Ther 2011; 11(4): 307– 320.

32. Vorburger SA, Hunt KK. Adenoviral gene teraphy. Oncologist 2002; 7(1): 46– 59.

33. Raper SE, Yudkoff M, Chirmule N et al. A pilot study of in vivo liver‑ directed gene transfer with an adenoviral vector in partial orthonine transcarbamylase deficiency. Hum Gene Ther 2002; 13(1): 163– 175.

34. [homepage on the Internet]. U.S. National Institutes of Health, USA; [updated 2014 May, cited 2015 March 1]. Available from: https:/ / ct2/ results?term=adenoviral+vector&recr=Open&no_unk=Y&phase=0.

Paediatric clinical oncology Surgery Clinical oncology
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account